Intranasal Insulin Treatment Attenuates Metabolic Distress and Early Brain Injury After Subarachnoid Hemorrhage in Mice.
Early brain injury
Intranasal insulin treatment
Metabolic distress
Subarachnoid hemorrhage
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
5
6
2020
medline:
30
9
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Intranasal administration of insulin to the brain bypasses the blood brain barrier (BBB) and can increase cerebral glucose uptake and prevent energy failure. Intranasal insulin treatment has shown neuroprotective effects in multiple central nervous system (CNS) lesions, but the effects of intranasal insulin on the metabolic and pathological process of subarachnoid hemorrhage (SAH) are not clear. This study is designed to explore the effects of intranasal insulin treatment on metabolic distress and early brain injury (EBI) after experimental SAH. SAH model was built by endovascular filament perforation method in adult male C57BL/6J mice, and then, insulin was administrated via intranasal route at 0, 24, and 48 h post-SAH. EBI was assessed according to the neurological performance, BBB damage, brain edema, neuroinflammatory reaction, and neuronal apoptosis at each time point. To evaluate metabolic conditions, microdialysis was used to continuously monitor the real-time levels of glucose, pyruvate, and lactate in interstitial fluid (ISF) in living animals. The mRNA and protein expression of glucose transporter-1 and 3 (GLUT-1 and -3) were also tested by RT-PCR and Western blot in brain after SAH. Compared to vehicle, intranasal insulin treatment promoted the relative mRNA and protein levels of GLUT-1 in SAH brain (0.98 ± 0.020 vs 0.33 ± 0.016 at 24 h, 0.91 ± 0.25 vs 0.21 ± 0.013 at 48 h and 0.94 ± 0.025 vs 0.28 ± 0.015 at 72 h in mRNA/0.96 ± 0.023 vs 0.36 ± 0.015 at 24 h, 0.91 ± 0.022 vs 0.22 ± 0.011 at 48 h and 0.95 ± 0.024 vs 0.27 ± 0.014 at 72 h in protein, n = 8/Group, p < 0.001). Similar results were also observed in GLUT-3. Intranasal insulin reduced the lactate/pyruvate ratio (LPR) and increased ISF glucose level. It also improved neurological dysfunction, BBB damage, and brain edema and attenuated the levels of pro-inflammatory cytokines as well as neuronal apoptosis after SAH. The intranasal insulin treatment protects brain from EBI possibly via improving metabolic distress after SAH.
Sections du résumé
BACKGROUND
Intranasal administration of insulin to the brain bypasses the blood brain barrier (BBB) and can increase cerebral glucose uptake and prevent energy failure. Intranasal insulin treatment has shown neuroprotective effects in multiple central nervous system (CNS) lesions, but the effects of intranasal insulin on the metabolic and pathological process of subarachnoid hemorrhage (SAH) are not clear. This study is designed to explore the effects of intranasal insulin treatment on metabolic distress and early brain injury (EBI) after experimental SAH.
METHODS
SAH model was built by endovascular filament perforation method in adult male C57BL/6J mice, and then, insulin was administrated via intranasal route at 0, 24, and 48 h post-SAH. EBI was assessed according to the neurological performance, BBB damage, brain edema, neuroinflammatory reaction, and neuronal apoptosis at each time point. To evaluate metabolic conditions, microdialysis was used to continuously monitor the real-time levels of glucose, pyruvate, and lactate in interstitial fluid (ISF) in living animals. The mRNA and protein expression of glucose transporter-1 and 3 (GLUT-1 and -3) were also tested by RT-PCR and Western blot in brain after SAH.
RESULTS
Compared to vehicle, intranasal insulin treatment promoted the relative mRNA and protein levels of GLUT-1 in SAH brain (0.98 ± 0.020 vs 0.33 ± 0.016 at 24 h, 0.91 ± 0.25 vs 0.21 ± 0.013 at 48 h and 0.94 ± 0.025 vs 0.28 ± 0.015 at 72 h in mRNA/0.96 ± 0.023 vs 0.36 ± 0.015 at 24 h, 0.91 ± 0.022 vs 0.22 ± 0.011 at 48 h and 0.95 ± 0.024 vs 0.27 ± 0.014 at 72 h in protein, n = 8/Group, p < 0.001). Similar results were also observed in GLUT-3. Intranasal insulin reduced the lactate/pyruvate ratio (LPR) and increased ISF glucose level. It also improved neurological dysfunction, BBB damage, and brain edema and attenuated the levels of pro-inflammatory cytokines as well as neuronal apoptosis after SAH.
CONCLUSIONS
The intranasal insulin treatment protects brain from EBI possibly via improving metabolic distress after SAH.
Identifiants
pubmed: 32495315
doi: 10.1007/s12028-020-01011-4
pii: 10.1007/s12028-020-01011-4
doi:
Substances chimiques
Insulin
0
Neuroprotective Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-166Références
Kusaka G, et al. Signaling pathways for early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2004;24(8):916–25.
pubmed: 15362722
doi: 10.1097/01.WCB.0000125886.48838.7E
Pluta RM, et al. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res. 2009;31(2):151–8.
pubmed: 19298755
pmcid: 2706525
doi: 10.1179/174313209X393564
Vespa P, et al. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab. 2005;25(6):763–74.
pubmed: 15716852
pmcid: 4347944
doi: 10.1038/sj.jcbfm.9600073
Marcoux J, et al. Persistent metabolic crisis as measured by elevated cerebral microdialysis lactate-pyruvate ratio predicts chronic frontal lobe brain atrophy after traumatic brain injury. Crit Care Med. 2008;36(10):2871–7.
pubmed: 18766106
doi: 10.1097/CCM.0b013e318186a4a0
Stein NR, et al. Early cerebral metabolic crisis after TBI influences outcome despite adequate hemodynamic resuscitation. Neurocrit Care. 2012;17(1):49–57.
pubmed: 22528283
doi: 10.1007/s12028-012-9708-y
Kurtz P, et al. Anemia is associated with metabolic distress and brain tissue hypoxia after subarachnoid hemorrhage. Neurocrit Care. 2010;13(1):10–6.
pubmed: 20383611
doi: 10.1007/s12028-010-9357-y
Oddo M, et al. Induced normothermia attenuates cerebral metabolic distress in patients with aneurysmal subarachnoid hemorrhage and refractory Fever. Stroke. 2009;40(5):1913–6.
pubmed: 19246699
doi: 10.1161/STROKEAHA.108.534115
Kurtz P, et al. Systemic glucose variability predicts cerebral metabolic distress and mortality after subarachnoid hemorrhage: a retrospective observational study. Crit Care. 2014;18(3):R89.
pubmed: 24887049
pmcid: 4056693
doi: 10.1186/cc13857
de Lima Oliveira M, et al. Brain metabolic crisis in traumatic brain injury: what does it mean? J Neurotrauma. 2014;31(20):1750–1.
pubmed: 24915159
doi: 10.1089/neu.2014.3386
Schulingkamp RJ, et al. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev. 2000;24(8):855–72.
pubmed: 11118610
doi: 10.1016/S0149-7634(00)00040-3
Plum L, Schubert M, Bruning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005;16(2):59–65.
pubmed: 15734146
doi: 10.1016/j.tem.2005.01.008
Cashion MF, Banks WA, Kastin AJ. Sequestration of centrally administered insulin by the brain: effects of starvation, aluminum, and TNF-alpha. Horm Behav. 1996;30(3):280–6.
pubmed: 8918685
doi: 10.1006/hbeh.1996.0034
Thorne RG, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127(2):481–96.
pubmed: 15262337
doi: 10.1016/j.neuroscience.2004.05.029
Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654–73.
pubmed: 19877171
doi: 10.1002/jps.21924
Lochhead JJ, et al. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab. 2015;35(3):371–81.
pubmed: 25492117
doi: 10.1038/jcbfm.2014.215
Reger MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323–31.
pubmed: 18430999
pmcid: 2804944
doi: 10.3233/JAD-2008-13309
Pang Y, et al. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience. 2016;318:157–65.
pubmed: 26777890
pmcid: 4753102
doi: 10.1016/j.neuroscience.2016.01.020
Chen Y, et al. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol. 2014;261:610–9.
pubmed: 24918340
doi: 10.1016/j.expneurol.2014.06.004
Brabazon F, et al. Intranasal insulin treatment of an experimental model of moderate traumatic brain injury. J Cereb Blood Flow Metab. 2017;37(9):3203–18.
pubmed: 28058996
pmcid: 5584695
doi: 10.1177/0271678X16685106
Lioutas VA, et al. Intranasal insulin and insulin-like growth factor 1 as neuroprotectants in acute ischemic stroke. Transl Stroke Res. 2015;6(4):264–75.
pubmed: 26040423
pmcid: 4861046
doi: 10.1007/s12975-015-0409-7
Hasegawa Y, et al. Preservation of tropomyosin-related kinase B (TrkB) signaling by sodium orthovanadate attenuates early brain injury after subarachnoid hemorrhage in rats. Stroke. 2011;42(2):477–83.
pubmed: 21193742
doi: 10.1161/STROKEAHA.110.597344
Sugawara T, et al. A new grading system evaluating bleeding scale in filament perforation subarachnoid hemorrhage rat model. J Neurosci Methods. 2008;167(2):327–34.
pubmed: 17870179
doi: 10.1016/j.jneumeth.2007.08.004
Quintard H, et al. Improvement of neuroenergetics by hypertonic lactate therapy in patients with traumatic brain injury is dependent on baseline cerebral lactate/pyruvate ratio. J Neurotrauma. 2016;33(7):681–7.
pubmed: 26421521
pmcid: 4827289
doi: 10.1089/neu.2015.4057
Yan EB, et al. Post-traumatic hypoxia exacerbates neurological deficit, neuroinflammation and cerebral metabolism in rats with diffuse traumatic brain injury. J Neuroinflammation. 2011;8:147–8.
pubmed: 22034986
pmcid: 3215944
doi: 10.1186/1742-2094-8-147
Marks DR, et al. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci. 2009;29(20):6734–51.
pubmed: 19458242
pmcid: 2779219
doi: 10.1523/JNEUROSCI.1350-09.2009
Chen Y, et al. Intranasal insulin prevents anesthesia-induced cognitive impairment and chronic neurobehavioral changes. Front Aging Neurosci. 2017;9:136.
pubmed: 28539885
pmcid: 5424543
doi: 10.3389/fnagi.2017.00136
Garcia JH et al. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke, 1995. 26(4): p. 627–34; discussion 635.
Roof RL, et al. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol. 1996;138(2):246–51.
pubmed: 8620923
doi: 10.1006/exnr.1996.0063
Ostrowski RP, Colohan AR, Zhang JH. Molecular mechanisms of early brain injury after subarachnoid hemorrhage. Neurol Res. 2006;28(4):399–414.
pubmed: 16759443
doi: 10.1179/016164106X115008
Fujii M, et al. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res. 2013;4(4):432–46.
pubmed: 23894255
pmcid: 3719879
doi: 10.1007/s12975-013-0257-2
Keep RF, et al. Ischemia-induced endothelial cell dysfunction. Acta Neurochir Suppl. 2005;95:399–402.
pubmed: 16463889
doi: 10.1007/3-211-32318-X_81
Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab. 2007;27(11):1766–91.
pubmed: 17579656
pmcid: 2094104
doi: 10.1038/sj.jcbfm.9600521
Bonkowski D, et al. The CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival. Fluids Barriers CNS. 2011;8(1):8.
pubmed: 21349156
pmcid: 3042982
doi: 10.1186/2045-8118-8-8
Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97(6):512–23.
pubmed: 16166562
doi: 10.1161/01.RES.0000182903.16652.d7
Devraj K, et al. GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J Neurosci Res. 2011;89(12):1913–25.
pubmed: 21910135
doi: 10.1002/jnr.22738
Castro V, et al. Occludin regulates glucose uptake and ATP production in pericytes by influencing AMP-activated protein kinase activity. J Cereb Blood Flow Metab. 2018;38(2):317–32.
pubmed: 28718701
doi: 10.1177/0271678X17720816
Szablewski L. Glucose transporters in brain: in health and in Alzheimer’s disease. J Alzheimers Dis. 2017;55(4):1307–20.
pubmed: 27858715
doi: 10.3233/JAD-160841
Schlenk F, et al. Hyperglycemia and cerebral glucose in aneurysmal subarachnoid hemorrhage. Intensive Care Med. 2008;34(7):1200–7.
pubmed: 18320167
doi: 10.1007/s00134-008-1044-5
Oertel MF, et al. Cerebral energy failure after subarachnoid hemorrhage: the role of relative hyperglycolysis. J Clin Neurosci. 2007;14(10):948–54.
pubmed: 17669657
doi: 10.1016/j.jocn.2006.11.002
Fox PT, Raichle ME. Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc Natl Acad Sci U S A. 1986;83(4):1140–4.
pubmed: 3485282
pmcid: 323027
doi: 10.1073/pnas.83.4.1140
Fox PT, et al. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988;241(4864):462–4.
pubmed: 3260686
doi: 10.1126/science.3260686
Park CR, et al. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav. 2000;68(4):509–14.
pubmed: 10713291
doi: 10.1016/S0031-9384(99)00220-6
de la Monte SM. Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opin Drug Deliv. 2013;10(12):1699–709.
pubmed: 24215447
pmcid: 4551402
doi: 10.1517/17425247.2013.856877
Huang CC, Lee CC, Hsu KS. An investigation into signal transduction mechanisms involved in insulin-induced long-term depression in the CA1 region of the hippocampus. J Neurochem. 2004;89(1):217–31.
pubmed: 15030406
doi: 10.1111/j.1471-4159.2003.02307.x
Ahmadian G, et al. Tyrosine phosphorylation of GluR2 is required for insulin-stimulated AMPA receptor endocytosis and LTD. EMBO J. 2004;23(5):1040–50.
pubmed: 14976558
pmcid: 380981
doi: 10.1038/sj.emboj.7600126
Yu Q, et al. Intranasal insulin increases synaptic protein expression and prevents anesthesia-induced cognitive deficits through mTOR-eEF2 pathway. J Alzheimers Dis. 2019;70(3):925–36.
pubmed: 31306126
doi: 10.3233/JAD-190280
Dandona P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001;86(7):3257–65.
pubmed: 11443198
Aljada A, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab. 2002;87(3):1419–22.
pubmed: 11889219
doi: 10.1210/jcem.87.3.8462
Spielman LJ, et al. Insulin modulates in vitro secretion of cytokines and cytotoxins by human glial cells. Curr Alzheimer Res. 2015;12(7):684–93.
pubmed: 26159205
doi: 10.2174/1567205012666150710104428
D’Souza R, et al. Insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies. AAPS PharmSciTech. 2005;6(2):E184–9.
pubmed: 16353976
pmcid: 2750530
doi: 10.1208/pt060227